Key Appointment to take Company Strategy Forward

Nanoliter-scale immunoassays provider Gyros Protein Technologies AB has appointed Dr Frank Whitney as Chairman of the Board. This is regarded as a key milestone in the company’s strategy to build strong market position through ongoing development of its peptide synthesizers and reagents, commercial expansion and growth via acquisition. David Patteson, prior chairman of Protein Technologies, Inc. remains as a Director.

Dr. Witney has over 30 years of experience in leadership and innovation in the life science industry. Most recently he was President and CEO of Affymetrix, which was acquired by Thermo Fisher Scientific in March 2016.  Prior to this, Dr. Witney was President and Chief Executive Officer of Dionex, leading to the company’s successful acquisition by Thermo Fisher Scientific in 2011. Earlier executive roles include President and CEO of Panomics, acquired by Affymetrix, and COO at Packard Biosciences, acquired by PerkinElmer, after which he served as President of their Life Sciences Group. Earlier in his career Dr. Witney held a series of positions at Bio-Rad Laboratories, including Group Operations Manager of the Life Science Group, leading efforts to enter rapidly growing markets for proteomic and bioassay technologies.

Dr. Witney holds a doctorate in molecular and cell biology from Indiana University, and was a post-doctoral fellow at the National Institutes of Health. He is also a member of the Board of Directors of Cerus Corporation and Exagen Diagnostics, Inc.

Dan Calvo, CEO of Gyros Protein Technologies, commented: “We are delighted that Frank has joined as Chairman. He brings with him a wealth of experience and knowledge in the field, and his guidance will be invaluable as we work to build Gyros Protein Technologies following the merger earlier this year.”

The company was established in March 2016 following the by the merger of Gyros AB and Protein Technologies, Inc.